SecBot SecBot
8-K ·Filed Jun 12, 2026

PHGE

BiomX Inc.
MIXED
Impact 5/10
Horizonweeks Processed5mo ago SEC0001213900-26-068026
8-K context-dependent: Items 3.01, 7.01
Actionable Insight ◆ Mixed

Track the company's progress on its compliance plan, particularly any capital raises or restructuring that could improve equity. Delisting risk remains significant if the plan fails, making PHGE a high-risk, event-driven trade. The extended timeline (2027) reduces near-term urgency.

DirectionMixed
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.5362
T+0 close · Jun 12, 2026 · via day close
Latest settled
−71.09%
T+60 · $0.1550
Vs SPY
−74.36%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 12 $0.5362entry
  2. T+1 · 5mo ago +3.49%α +1.72% · $0.5549
  3. T+5 · 5mo ago −3.04%α −3.71% · $0.5199
  4. T+20 · 4mo ago −56.73%α −58.51% · $0.2320
  5. T+60 · 2mo ago −71.09%α −74.36% · $0.1550
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BiomX Inc. received acceptance from NYSE American of its plan to regain compliance with continued listing standards, granting a plan period through September 25, 2027. The company had a stockholders' deficit of $(1.302 million) as of December 31, 2025 and losses in five recent fiscal years, leading to its non-compliance. While the plan acceptance provides a path to avoid delisting, the underlying financial weakness and high execution risk keep the outlook uncertain.

Key Facts

  • NYSE American accepted BiomX's compliance plan on June 10, 2026, with a plan period through September 25, 2027.
  • Non-compliance stemmed from stockholders' deficit of $1.302 million as of Dec 31, 2025 and losses from continuing operations in five recent fiscal years.
  • The company's stock will continue trading with a .BC (below compliance) indicator during the plan period.
  • If the company fails to regain compliance or make sufficient progress, delisting proceedings may be initiated.

Financial Impact

Stockholders' deficit of $1.302 million as of December 31, 2025, with ongoing losses from operations.

stockholdersEquity

Risk Factors

  • Failure to execute the compliance plan could lead to delisting and loss of liquidity.
  • Continued operating losses may further erode stockholders' equity and worsen compliance.
  • Going concern risk given historical losses and negative equity.

Market Snapshot

Exchange
NYSE
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-068026
Document: ea029450701ex99-1.htm0001213900-26-068026
Document: 0001213900-26-068026-index-headers.html0001213900-26-068026
Document: 0001213900-26-068026-index.html0001213900-26-068026
Document: 0001213900-26-068026.txt0001213900-26-068026

US Market Status

Market Closed · Opens in 4h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 12, 2026